Edit

BioMotiv

https://www.biomotiv.com

Last activity: 18.07.2023

Active

Invests in categories: DrugBioTechHealthTechDevelopmentPlatformTechnologyUniversityDeliveryHumanScience

BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million US and UK initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of programs.

Followers

1.08K

Portfolio

Mentions

Location: United States, Ohio, Cleveland

Employees: 11-50

Founded date: 2012

Investment Type: Accelerator

Portfolio 9

Date	Name	Website	Total Raised	Location
-	Allinaire	allinaire.com	-	United Sta...
-	SNO Bio	sno-bio.com	-	United Sta...
-	Aro Biothe...	arobiotx.com	$65.5M	United Sta...
-	Amphista	amphista.com	$60.5M	United Kin...
-	Koutif	koutiftherapeutics.com	-	United Sta...
-	Aleta Biot...	aletabio.com	-	United Sta...
-	OptiKira	optikira.com	-	-
-	Sujana	sujanabio.com	-	United Sta...
-	SapVax	sapvaxllc.com	-	United Sta...

Mentions in press and media 24

Date	Title	Description
08.02.2019	Rutgers scientists form immuno-oncology biotech to develop pipeline of TAM inhibitors	Raymond Birge There are thousands of immuno-oncology therapies in the global pipeline, and researchers from Rutgers are adding to that tally, with a family of compounds that could potentially be used in tandem with estab...
01.03.2016	BioMotiv announces new startup: Anti-cancer drug developer Z53 Therapeutics	The new potential product, developed by researchers out of Rutgers and SUNY Upstate, is providing a solution that would restore the function of zinc binding withing the mutant p53. They are calling the compounds “zinc metallochaperones.” As...
04.05.2015	Heart experts from Cleveland Clinic and Case Western team up: Sujana Biotech raising $5M	BioMotiv is the for-profit affiliate of University Hospitals’ Harrington Project, a $250 million initiative created to bridge the “valley of death” in drug development by accelerating the development and commercialization of medical breakth...
25.02.2015	AstraZeneca and Orca Pharmaceuticals announce research collaboration	AstraZeneca and Orca Pharmaceuticals announce research collaboration 25-02-2015 AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class RORγ inhibitors to treat auto-immune diseases. AstraZeneca and Or...
18.06.2014	Biotech startup developing prostate cancer treatment is raising $7.5M	A research team led by Michael Ohlmeyer, an associate professor of structural and chemical biology at Mount Sinai, discovered a way to trigger the death of certain tumor cells. The team found that two tumor suppressor genes, KLF6 and FOXO1,...
19.02.2014	BioAtla-BioMotiv licensing deal results in new biotech startup to develop IBD, cancer drugs	Consistent with BioMotiv’s business model, the new venture will manage development of the antibody through the proof-of-concept stage. BioMotiv, the for-profit component of the $250 million Harrington Project for Discovery & Development...
09.09.2013	Biotech accelerator BioMotiv, NYU unveil a new spinoff for inflammatory disease treatments	With funding from BioMotiv and NYU’s Innovation Venture Fund, Orca is working toward achieving proof of concept of an orally administered therapeutic for psoriasis in 2016. The announcement today did not disclose the amount of funding Orca ...
12.08.2013	Biotech accelerator BioMotiv gets a $20M commitment from new investor	BioMotiv CEO Baiju Shah A week after Cleveland's nascent biotech accelerator BioMotiv bumped its financial reserves to $46 million, Torrey Pines Investment has stepped in to offer a $20 million commitment and close ties to the Russian drug ...
05.08.2013	BioMotiv Secures $25M in Additional Capital	CLEVELAND, OH, >> Click here for more funding data on BioMotiv >> To export BioMotiv funding data to PDF and Excel, click here BioMotiv, a drug development accelerator based in Cleveland, Ohio, today announced that it has...
05.08.2013	BioMotiv Increases Capital to $46M	BioMotiv, a drug development accelerator based in Cleveland, Ohio, has increased its total capital to $46m. Backers included Nationwide Mutual Insurance Company and individual investors, who joined founding investors University Hospitals of...
05.08.2013	With $46M in tow, accelerator/investor BioMotiv puts to work a new model for drug development	The non-profit components of the Harrington Project award grant support and resources to physician-scientists who have made promising discoveries. BioMotiv is a mission-aligned commercial entity that in-licenses technologies, uses its own l...
04.12.2012	There’s a new twist to early stage drug discovery financing: technology without the team (video)	For-profit biotech accelerator BioMotiv aims to shake up the early stage, drug discovery financing space. The Cleveland, Ohio company wants to invest in early stage drug discovery ideas but doesn’t want to deal with management. It wants to ...
21.09.2012	The biotech valley of death has become the uncrossable canyon. Here’s one innovative approach to funding	Shah, who left his post as head of Northeast Ohio life sciences trade group BioEnterprise earlier this month, gave his first public presentation in his new role at the BioOhio Regional Annual Conference in Cleveland on Thursday. “You can’t ...
06.09.2012	BioMotiv Raises $21M in Funding	BioMotiv, a Cleveland, OK-based for-profit therapeutic accelerator, has raised $21m in funding. Backers include founding investors University Hospitals and the Harrington Family. The company intends to use the funding to launch operations a...
18.07.2012	Ohio business leader Baiju Shah to depart BioEnterprise for biotech investment fund	BioMotiv, though connected with the Harrington fund, is in the midst of its own $100 million fundraise “as it builds a portfolio of breakthrough discoveries.” Shah said the opportunity to lead BioMotiv was appealing because it’s consistent ...
-	BioMotiv announces new startup: Anti-cancer drug developer Z53 Therapeutics	BioMotiv, the drug development accelerator associated with Cleveland-based The Harrington Project, Rutgers University and the State University of New Jersey, has announced the creation of a new startup called Z53 Therapeutics. The company i...
-	Biotech startup developing prostate cancer treatment is raising $7.5M	A biotechnology startup that spun out of University Hospitals of Cleveland last year has raised its first big round of financing since its launch two years ago. Dual Therapeutics, which is developing therapeutics for prostate cancer, lung c...
-	BioAtla-BioMotiv licensing deal results in new biotech startup to develop IBD, cancer drugs	There’s a new biotech startup in town: Kodosil Bio. The by-product of a licensing deal between San Diego biologics developer BioAtla and Cleveland-based biotech incubator BioMotiv, the company will focus on development of a monoclonal antib...
-	Ohio business leader Baiju Shah to depart BioEnterprise for biotech investment fund	Updated to add comments from Shah Baiju Shah, for years a central public face in Greater Cleveland’s push to build its life science sector, is leaving his post in the region’s key trade group to lead a biotech commercialization project in t...
-	Heart experts from Cleveland Clinic and Case Western team up: Sujana Biotech raising $5M	A new set of therapeutics for inflammatory and vascular disorders is being developed in Cleveland – based on research from a trio of lauded cardiovascular researchers. Sujana Biotech just raised $800,000 of a potential $5 million round, acc...
-	With $46M in tow, accelerator/investor BioMotiv puts to work a new model for drug development	Nearly halfway to its goal of raising $100 million, an intriguing venture that’s part drug development accelerator and part early-stage investor has begun picking promising projects it hopes will someday become drugs that fill a market need...
-	There’s a new twist to early stage drug discovery financing: technology without the team (video)	For-profit biotech accelerator BioMotiv aims to shake up the early stage, drug discovery financing space. The Cleveland, Ohio company wants to invest in early stage drug discovery ideas but doesn’t want to deal with management. It wants to ...
-	Biotech accelerator BioMotiv, NYU unveil a new spinoff for inflammatory disease treatments	A biotech accelerator launched as part of a $250 million drug discovery initiative spearheaded by Cleveland’s University Hospitals has spun off its first company to develop promising technology for treating inflammatory diseases. Orca Pharm...
-	The biotech valley of death has become the uncrossable canyon. Here’s one innovative approach to funding	We often talk about innovation in terms of science and technology, but in today’s healthcare ecosystem, it’s just as important to innovate on the business side of things. That’s what the $250 million Harrington Project for Discovery & D...

BioMotiv

Portfolio 9

Mentions in press and media 24

Reviews 0